Risk factors
Dermata Therapeutics (DRMA) risk factors
Item 1A of every Dermata Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors91 risks43 new43 dropped18 reworded
Dermata shifted focus from prescription clinical trials to launching its Tome skincare line using OTC monograph pathways.
Filed Mar 26, 2026 - FY2024 10-K risk factors91 risks
Dermata Therapeutics is a pre-revenue clinical-stage biopharmaceutical company dependent on cash to Q3 2025. The company's lead products are XYNGARI and DMT410. Independent auditors express substantial doubt about the company's ability to continue as a going concern.
Filed Mar 17, 2025